Business News, September 18th, “More than 5,000 patients in Qingdao, more than 1,000 patients in Guangzhou, and some elementary schools and kindergartens in Zhejiang have been suspended. The incidence of red-eye disease in Hunan has exceeded the sum of incidence in the first eight months since September, and Yixing, Jiangsu, also began to appear. "Eye eye disease." A deputy director of ophthalmology who asked not to be named pointed out that the "red eye disease" has an outbreak cycle of 4 to 5 years, while the previous two red eye diseases spread throughout the country in 2002 and 2007 respectively. The outbreak of pink eye also brought business opportunities to some pharmaceutical companies.

To deepen the medical reform, the "Twelfth Five-Year Plan" outline involving the pharmaceutical distribution industry in the country is about to be issued. The new plan will benefit the national and regional pharmaceutical and commercial leading enterprises. The “draft plan for the development of the national pharmaceutical distribution industry (2011-2015)” draft for comment (hereinafter referred to as the “planning”) has ended the solicitation of comments from industry associations and societies, and is currently undergoing final adjustments after the opinions are brought together within the Ministry of Commerce.

According to an authoritative source from the Ministry of Commerce, due to the need for further adjustments and necessary document procedures, it will eventually be issued in the name of multiple departments. “The plan” is likely to be announced in November, and provincial and municipal plans will be formulated before the end of December. Printed." With emphasis on the "market allocation role" and "promotion of industry concentration," there is no doubt that the upcoming "Planning" will benefit the nation's and local leading medical and pharmaceutical companies.

Industry insiders said: "When soliciting opinions, everyone thought that the number of 1-2 companies in the country is likely to create a monopoly, so the final number may be about 3, but it will not be more. The target is reflected in the market share, and it is hoped that within five years, the annual sales of pharmaceutical wholesale 'Top 100' companies will account for over 80% of the total annual sales of the industry."

According to the ranking of pharmaceutical and commerce sales in 2009, the top three of China National Medicines, Shangyu Pharmaceutical and Kyushu Tong, Nanjing Pharmaceutical, Guangzhou Pharmaceutical, and Anhui Huayuan followed closely. Among them, Sinopharm Group’s 2009 sales revenue was RMB 65 billion, which was set in 2010. The target is 80 billion yuan.

However, due to restructuring, the new drug is difficult to predict the exact amount of revenue, but its planning, revenue in 2012 reached 50 billion yuan, in 2013 the sales of more than 35 million varieties of more than 35, 2015 revenue reached 80 billion yuan.

All kinds of signs indicate that large-scale pharmaceutical and commercial enterprises have begun to strengthen their control over the regional distribution market and restructuring is under way. Some experts believe that the government protection and policy support that many companies have obtained will, on the one hand, cause them to form a relative monopoly and gain a high market share, but it will also reduce the pressure on their survival and weaken their competitiveness. The real competitiveness is actually discounted. "It is the future for investors to buy stocks, and the market is actually too. We must not only look at the current size, but also look at the continued profitability in the future." Insiders pointed out.